NCE-1 Intelligence & Market Opportunity

Forzinity

Elamipretide

Mitochondrial Dysfunction Agent

Subcutaneous Solution

Forzinity is a mitochondrial-targeted therapy for Barth syndrome in patients weighing 30 kg or more. It stabilizes mitochondrial function to improve energy production and muscle strength, administered via subcutaneous injection.

Approval Date

19-Sep-25

NCE-1 Date

19-Sep-29

NCE Date

19-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Elamipretide

Innovator

STEALTH BIOTHERAPEUTICS INC

Dosage Form

Subcutaneous Solution

Strength

EQ 280 mg base/3.5 mL (EQ 80 mg base/mL)

Therapeutic Category

Mitochondrial Dysfunction Agent

Usage

To improve muscle strength in patients with Barth syndrome weighing at least 30 kg

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.